Paratek Pharmaceuticals (NASDAQ:PRTK) will post its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Paratek Pharmaceuticals to post earnings of ($1.16) per share for the quarter.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.19) by $0.09. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.89 million. On average, analysts expect Paratek Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
NASDAQ PRTK traded up $0.09 during trading on Wednesday, reaching $3.34. 6,036 shares of the company’s stock were exchanged, compared to its average volume of 232,864. Paratek Pharmaceuticals has a fifty-two week low of $3.10 and a fifty-two week high of $12.30. The company has a market capitalization of $105.37 million, a price-to-earnings ratio of -0.93 and a beta of 1.76. The company has a quick ratio of 13.95, a current ratio of 14.06 and a debt-to-equity ratio of 14.48. The stock has a fifty day moving average price of $3.64.
PRTK has been the subject of a number of research reports. Wedbush raised their price objective on Roku from $55.00 to $65.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research lowered Green Plains Partners from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. HC Wainwright restated a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Finally, LADENBURG THALM/SH SH restated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $23.71.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Story: Institutional Investors
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.